Mike is a General Partner of Advanced Technology Ventures (ATV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Palo Alto, CA office, where he also serves as a General Partner and Team Leader for Lightstone Ventures. His representative investments include Altura Medical, Ardian (acquired by Medtronic), EndoGastric Solutions, GI Dynamics (ASX: GID), GluMetrics, Holaira, MicroVention (acquired by Terumo), NeuroVista, Plexxikon (acquired by Daiichi Sankyo), PowerVision, Second Genome, and TranS1 (NASDAQ: TSON).
Featured on the Forbes Midas List of top technology investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, sits on the Tuck MBA Advisory Board, and is an advisory board member to the UCSF/Berkeley Venture Innovation Program.
Earlier in his career, Mike served as the Director of Business Development for Inhale Therapeutic Systems (now Nektar Therapeutics, NASDAQ: NKTR), a venture-backed pulmonary drug delivery company that went public in 1994. At Inhale, Mike led partnering activities with a number of pharmaceutical and biotechnology companies in the U.S., Europe, and Japan. Mike also was a Principal at The Wilkerson Group, a leading management consulting firm focused exclusively on healthcare. At The Wilkerson Group, Mike helped establish the firm’s offices in London and San Francisco.
Mike holds an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College and a B.S. from Lehigh University.
Ardian (acquired by Medtronic)
GI Dynamics (ASX: GID)
MicroVention (acquired by Terumo)
Plexxikon (acquired by Daiichi Sankyo)
Trans1 (NASDAQ: TSON)